Amlodipine/irbesartan - Sanofi
Alternative Names: Aimix Combination Tablets HD; Aimix Combination Tablets LD; Amlodipine besilate/irbesartan; Aprovasc; DSP-8153; Irbesartan/amlodipine; Irbesartan/amlodipine besilateLatest Information Update: 05 Nov 2023
At a glance
- Originator sanofi-aventis
- Developer Handok Inc; Sanofi; Sumitomo Pharma
- Class Antihypertensives; Biphenyl compounds; Dihydropyridines; Small molecules; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypertension
- Phase I Unspecified
Most Recent Events
- 21 Apr 2023 Handok completes a phase I trial for Unspecified indication (In volunteers) in South Korea (PO) (NCT05688098)
- 23 Sep 2022 Phase-I clinical trials in Unspecified indication (In volunteers) in South Korea (PO) (NCT05688098)
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma